ERBB2 and neoplasm: These findings demonstrate that T-DXd provides durable clinical benefits and meaningful survival outcomes, particularly in Immunohistochemistry 3 + tumors, supporting its role as a tumor-agnostic therapy for patients with HER2-expressing solid tumors and offering an effective treatment option for patients with limited alternatives.